Bacterial Vaginosis Linked to Increased STI Co-Infection, Finds National Study of 1.5 Million Women from Quest Diagnostics
Quest Diagnostics (NYSE: DGX) and Hologic, Inc. reported a Health Trends study using deidentified molecular lab data from 1.5 million women tested at Quest from 2022-2024. BV was found in 38.7% of cases; 12.0% of BV-positive women also had at least one STI versus 3.8% of BV-negative. BV-positive status showed higher odds of chlamydia, gonorrhea, and trichomonas.
How this was made
The 30-second read
Why it matters
The study reports a strong association between BV positivity and higher odds of several non-viral STIs, reinforcing the case for comprehensive molecular testing from a single specimen.
Market read
For traders, this is a clinical-evidence headline tied to Quest’s diagnostics capabilities, but it lacks direct financial disclosures.
What to watch
The study notes limitations (single national lab dataset, missing patient risk-factor details), which could temper how quickly clinicians change ordering behavior.
Background
BV is common in women and can present with symptoms overlapping other STIs, complicating diagnosis; CDC recommends STI testing when BV is present.
Ticker impact
Quest Diagnostics analyzed molecular lab data from 1.5M women and reported BV-positive patients had higher STI co-infection odds.
Limited near-term impact on DGX shares; any effect is indirect via perceived diagnostic leadership.
The article is a large retrospective dataset and guideline-supporting evidence, with no new revenue guidance, contracts, approvals, or enforcement actions disclosed.
Market effects
Supports demand for comprehensive molecular STI testing workflows in women’s health, potentially benefiting diagnostic testing providers and assay ecosystems.
No clear regional market linkage; US-focused dataset.
Primarily US clinical practice evidence; limited direct global read-through without international guideline adoption details.
Counterpoint
Because this is retrospective lab-data analysis without new product commercialization or reimbursement changes, it may not translate into measurable near-term testing volume.
Key entities
- companyQuest Diagnostics
Conducted the Health Trends study using de-identified aggregated molecular lab data from 2022 to 2024.
- companyHologic, Inc.
Co-developed the study with Quest; mentioned as a partner in the analysis.
- publicationO&G Open
Peer-reviewed companion journal where the findings were published.
- regulatorCDC
Recommends STI testing for women with BV due to symptom overlap.
